Literature DB >> 22421939

Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.

Margarethe Przewoznik1, Nadine Hömberg, Marcella Naujoks, Johann Pötzl, Niklas Münchmeier, Christoph D Brenner, David Anz, Carole Bourquin, Peter J Nelson, Martin Röcken, Ralph Mocikat.   

Abstract

During inflammation and in transplantable tumor models, natural killer (NK) cells are recruited to pathologic tissues and activated to produce proinflammatory cytokines favoring adaptive immune responses of the T-helper type 1 (Th1) type. Interferon (IFN)-γ is needed to induce chemokines that attract NK cells in transplanted tumors. Nothing, however, is known on NK-cell migration in spontaneous tumors. As effective recruitment is a prerequisite for therapeutic NK-cell transfer, we investigated the cytokine milieu and the mechanisms that are instrumental for NK-cell accumulation in an endogenous tumor model. We make use of λ-myc transgenic mice that harbor the c-myc oncogene and develop spontaneous B-cell lymphoma. In contrast to lymphomas induced by tumor cell injection, virtually no IFN-γ produced by NK or by other cells was present in the tumor environment, particularly in advanced stages. Dendritic cells showed an impaired expression of interleukin-12, which is suggestive of deficient Th1 priming. The IFN-γ-dependent chemokines CXCL9 and CXCL10 were pivotal for NK-cell migration in the endogenous lymphoma model. Although IFN-γ was absent in late tumor stages, there was still expression of CXCL9 and CXCL10 with an ongoing influx of NK cells. The results demonstrate that transplantable tumor models do not reflect the situation as found in endogenously arising neoplasia, because in the latter, effective Th1 and cytotoxic T-lymphocyte responses are presumably not induced because of impaired IFN-γ production. The data also suggest that CXCL9 and CXCL10 production and NK-cell migration become independent of IFN-γ during tumor progression, and therefore support approaches of adoptive NK-cell transfer that hold promise for treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421939     DOI: 10.1097/CJI.0b013e318247440a

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  8 in total

1.  Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.

Authors:  Veronika Bachanova; Daniel J Weisdorf; Tao Wang; Steven G E Marsh; Elizabeth Trachtenberg; Michael D Haagenson; Stephen R Spellman; Martha Ladner; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Sarah A Cooley
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-21       Impact factor: 5.742

Review 2.  CXCL9: evidence and contradictions for its role in tumor progression.

Authors:  Qiang Ding; Panpan Lu; Yujia Xia; Shuping Ding; Yuhui Fan; Xin Li; Ping Han; Jingmei Liu; Dean Tian; Mei Liu
Journal:  Cancer Med       Date:  2016-10-10       Impact factor: 4.452

3.  Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.

Authors:  Heleen H Van Acker; Ottavio Beretta; Sébastien Anguille; Lien De Caluwé; Angela Papagna; Johan M Van den Bergh; Yannick Willemen; Herman Goossens; Zwi N Berneman; Viggo F Van Tendeloo; Evelien L Smits; Maria Foti; Eva Lion
Journal:  Oncotarget       Date:  2017-02-21

4.  A longitudinal big data approach for precision health.

Authors:  Sophia Miryam Schüssler-Fiorenza Rose; Kévin Contrepois; Kegan J Moneghetti; Wenyu Zhou; Tejaswini Mishra; Samson Mataraso; Orit Dagan-Rosenfeld; Ariel B Ganz; Jessilyn Dunn; Daniel Hornburg; Shannon Rego; Dalia Perelman; Sara Ahadi; M Reza Sailani; Yanjiao Zhou; Shana R Leopold; Jieming Chen; Melanie Ashland; Jeffrey W Christle; Monika Avina; Patricia Limcaoco; Camilo Ruiz; Marilyn Tan; Atul J Butte; George M Weinstock; George M Slavich; Erica Sodergren; Tracey L McLaughlin; Francois Haddad; Michael P Snyder
Journal:  Nat Med       Date:  2019-05-08       Impact factor: 53.440

5.  Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.

Authors:  Martin Röcken; Ralph Mocikat; Fatima Ahmetlic; Josia Fauser; Tanja Riedel; Vera Bauer; Carolin Flessner; Nadine Hömberg; Roman Hennel; Ellen Brenner; Kirsten Lauber
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

Review 6.  CD47 as a promising therapeutic target in oncology.

Authors:  Hai Zhao; Shuangshuang Song; Junwei Ma; Zhiyong Yan; Hongwei Xie; Ying Feng; Shusheng Che
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

Review 7.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

8.  Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice.

Authors:  Yaya Chu; Gaurav Nayyar; Susiyan Jiang; Jeremy M Rosenblum; Patrick Soon-Shiong; Jeffrey T Safrit; Dean A Lee; Mitchell S Cairo
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.